BRD4770 functions as a novel ferroptosis inhibitor to protect against aortic dissection

Smooth muscle cell (SMC) loss is the characteristic feature in the pathogenesis of aortic dissection (AD), and ferroptosis is a novel iron-dependent regulated cell death driven by the excessive lipid peroxidation accumulation. However, whether targeting ferroptosis is an effective approach for SMC l...

Full description

Saved in:
Bibliographic Details
Published inPharmacological research Vol. 177; p. 106122
Main Authors Chen, Yue, Yi, Xin, Huo, Bo, He, Yi, Guo, Xian, Zhang, Zihao, Zhong, Xiaoxuan, Feng, Xin, Fang, Ze-Min, Zhu, Xue-Hai, Wei, Xiang, Jiang, Ding-Sheng
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.03.2022
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Smooth muscle cell (SMC) loss is the characteristic feature in the pathogenesis of aortic dissection (AD), and ferroptosis is a novel iron-dependent regulated cell death driven by the excessive lipid peroxidation accumulation. However, whether targeting ferroptosis is an effective approach for SMC loss and AD treatment remains unclear. Here, we found that the iron level, ferroptosis-related molecules TFR, HOMX1, ferritin and the lipid peroxidation product 4-hydroxynonenal were increased in the aorta of AD. Then, we screened several inhibitors of histone methyltransferases and found that BRD4770 had a protective effect on cystine deprivation-, imidazole ketone erastin- or RSL3-induced ferroptosis of SMCs. The classic ferroptosis pathways, System Xc--GPX4, FSP1-CoQ10 and GCH1-BH4 pathways which were inhibited by ferroptosis inducers, were re-activated by BRD4770 via inhibiting mono-, di- and tri- methylated histone H3 at lysine 9 (H3K9me1/2/3). RNA-sequencing analysis revealed that there was a positive feedback regulation between ferroptosis and inflammatory response, and BRD4770 can reverse the effects of inflammation activation on ferroptosis. More importantly, treatment with BRD4770 attenuated aortic dilation and decreased morbidity and mortality in a β-Aminopropionitrile monofumarate-induced mouse AD model via inhibiting the inflammatory response, lipid peroxidation and ferroptosis. Taken together, our findings demonstrate that ferroptosis is a novel and critical pathological mechanism that is involved in SMC loss and AD development. BRD4770 is a novel ferroptosis inhibitor and has equivalent protective effect to Ferrostatin-1 at the optimal concentration. Translating insights into the anti-ferroptosis effects of BRD4770 may reveal a potential therapeutic approach for targeting SMC ferroptosis in AD. [Display omitted] •Ferroptosis is a novel and critical pathological mechanism involved in SMC loss and AD development.•BRD4770 is a novel inhibitor of ferroptosis and protects against SMC ferroptosis via maintaining redox homeostasis.•BRD4770 relieves BAPN-induced AD by inhibiting ferroptosis and inflammatory cell infiltration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1043-6618
1096-1186
DOI:10.1016/j.phrs.2022.106122